肝癌：纳武单抗：肝细胞癌的制胜之选？ - Suppr

Suppr

超能文献

Liver cancer: Nivolumab: checkmate for hepatocellular carcinoma?

作者信息

Ray Katrina

出版信息

Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):326. doi: 10.1038/nrgastro.2017.62. Epub 2017 May 10.

DOI:10.1038/nrgastro.2017.62

PMID:28487550

Abstract

摘要

相似文献

Liver cancer: Nivolumab: checkmate for hepatocellular carcinoma?肝癌：纳武单抗：肝细胞癌的制胜之选？

Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):326. doi: 10.1038/nrgastro.2017.62. Epub 2017 May 10.

Immunotherapy: Nivolumab keeps HCC in check and opens avenues for checkmate.免疫疗法：纳武单抗可控制肝癌并为战胜癌症开辟途径。

Nat Rev Clin Oncol. 2017 Jul;14(7):392. doi: 10.1038/nrclinonc.2017.70. Epub 2017 May 9.

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.纳武利尤单抗对比研究者选择的标准单药疗法用于复发性或转移性头颈部鳞状细胞癌（CheckMate 141）：一项随机3期试验的健康相关生活质量结果

Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.在CheckMate 025研究中，接受纳武单抗与依维莫司治疗的晚期肾细胞癌患者的生活质量：一项随机、开放标签的3期试验。

Lancet Oncol. 2016 Jul;17(7):994-1003. doi: 10.1016/S1470-2045(16)30125-5. Epub 2016 Jun 6.

Nivolumab for the treatment of hepatocellular carcinoma.纳武利尤单抗治疗肝细胞癌。

Expert Rev Anticancer Ther. 2018 Dec;18(12):1169-1175. doi: 10.1080/14737140.2018.1535315. Epub 2018 Oct 22.

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.纳武利尤单抗单药治疗复发性转移性尿路上皮癌（CheckMate 032）：一项多中心、开放标签、两阶段、多臂1/2期试验。

Lancet Oncol. 2016 Nov;17(11):1590-1598. doi: 10.1016/S1470-2045(16)30496-X. Epub 2016 Oct 9.

Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study.

Lancet Oncol. 2022 Jan;23(1):4-6. doi: 10.1016/S1470-2045(21)00651-3. Epub 2021 Dec 13.

A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.一项纳武利尤单抗对比研究者选择的治疗方案用于复发性头颈部鳞状细胞癌的随机、开放标签、III 期临床试验：Checkmate 141 中亚洲患者与全球人群的亚组分析。

Oral Oncol. 2017 Oct;73:138-146. doi: 10.1016/j.oraloncology.2017.07.023. Epub 2017 Sep 1.

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.纳武利尤单抗用于复发性头颈部鳞状细胞癌

N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8.

Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆.纳武利尤单抗治疗复发性或转移性头颈部癌的成本效益分析☆。

Oral Oncol. 2017 Nov;74:49-55. doi: 10.1016/j.oraloncology.2017.09.017. Epub 2017 Sep 23.

引用本文的文献

SPP1+ tumor-associated macrophages define a high-risk subgroup and inform personalized therapy in hepatocellular carcinoma.SPP1+肿瘤相关巨噬细胞定义了一个高危亚组，并为肝细胞癌的个性化治疗提供依据。

Front Oncol. 2025 Jul 1;15:1606195. doi: 10.3389/fonc.2025.1606195. eCollection 2025.

The causal relationship between immune cells and hepatocellular carcinoma: a Mendelian randomization (MR).免疫细胞与肝细胞癌之间的因果关系：孟德尔随机化研究（MR）

Ecancermedicalscience. 2024 Nov 8;18:1794. doi: 10.3332/ecancer.2024.1794. eCollection 2024.

A novel prognostic model based on immunogenic cell death-related genes for improved risk stratification in hepatocellular carcinoma patients.一种基于免疫原性细胞死亡相关基因的新型预后模型，用于改善肝细胞癌患者的风险分层。

J Cancer Res Clin Oncol. 2023 Sep;149(12):10255-10267. doi: 10.1007/s00432-023-04950-5. Epub 2023 Jun 3.

A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma.原发性和转移性肝细胞癌的多细胞生态系统单细胞图谱。

Nat Commun. 2022 Aug 6;13(1):4594. doi: 10.1038/s41467-022-32283-3.

本文引用的文献

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。

Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验